Strategic Synergy Novozymes has merged with Chr. Hansen to form Novonesis, signaling a broader biosolutions platform and expanded capabilities across enzymatic, microbial, and protein solutions. This presents cross-sell opportunities to leverage combined product lines, especially in industries seeking integrated biological solutions.

Protein Innovation Recent headlines emphasize development of protein ingredients through precision fermentation, including non-GM yeast capabilities. This creates upside for selling to food and beverage players pursuing plant-based portfolios and clean-label ingredients, as well as collaborations with dairy and consumer brands investing in novel proteins.

Strategic Partnerships Active and upcoming partnerships with Arla, DMK MILRAM, Kerry Group, Certis Europe, and others indicate a customer-oriented growth mindset and collaborative R&D. Use these alliances to position Novonesis as a co-innovation partner for scalable biosolutions across dairy, plant-based, and crop protection segments.

Global Footprint With a presence across 130 markets and a revenue range of one to several billions, Novonesis targets large-scale adoption of biosolutions. Focus sales efforts on regions with high agri-food and industrial demand for renewable energy, sustainable production, and low-temperature processing capabilities.

Technology Stack Leveraging AWS, SAP, Salesforce and other enterprise tools signals mature digital capabilities for customer success, supply chain, and data analytics. Position as a partner that can integrate with customers’ systems for streamlined deployment, traceability, and performance tracking of biosolutions at scale.